Will 45% Of Work At Moderna Be Completed By AI By 2030? Yes image

Moderna Aims for 45% AI-Driven Workforce by 2030: The Future of Biotech Automation

Date: Jul 17, 2025

Category: Health & Technology


The landscape of high-level cognitive work is undergoing a seismic shift, with automation and artificial intelligence (AI) poised to redefine talent management across industries. Moderna, a trailblazer in biotechnology, is at the forefront of this transformation. The company has set an ambitious goal: by 2030, 45% of its work will be completed by AI-driven systems. This rapid adoption of AI is not just about automating repetitive tasks; it extends to complex decision-making and research processes that were once the exclusive domain of human experts. Within the next two years, experts predict that up to 95% of cognitive tasks currently performed by humans could be executed more efficiently by AI. This shift will fundamentally alter how companies like Moderna structure their workforce, blending human expertise with advanced AI software robots. For Moderna, leveraging AI means accelerating drug discovery, optimizing clinical trials, and streamlining operations. The integration of AI technologies enables faster data analysis, improved accuracy, and significant cost savings. As a result, the company can bring innovative therapies to market more quickly and efficiently than ever before. The move towards an AI-driven workforce also presents new challenges and opportunities for talent management. Companies will need to invest in upskilling their employees, fostering collaboration between humans and machines, and rethinking traditional roles. Those that adapt quickly, like Moderna, are likely to gain a significant competitive edge in the evolving biotech landscape. As automation continues to advance, the future of work in biotechnology—and beyond—will be shaped by the seamless integration of AI and human ingenuity. Read the source »

Share on:

You may also like these similar articles